One-third of women confused about perimenopause: what Canadian patients need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A study published July 15, 2026, in Menopause, the journal of The Menopause Society, found that 34% of more than 7,600 US women aged 35 and older did not know whether they were in perimenopause, with uncertainty climbing to 42% among women aged 40 to 44. Perimenopause is the multi-year transition before menopause when hormone levels fluctuate unpredictably, typically beginning in the mid-40s and lasting four to eight years, though onset can occur earlier. For Canadian patients, the findings land in a system where no definitive diagnostic test exists, where many family physicians receive limited training in menopause care, and where access to a specialist who can interpret the full symptom picture depends heavily on which province you live in.

The study, a mixed-methods survey led by Dr. Stephanie Faubion, medical director of The Menopause Society, identified three main drivers of uncertainty. Symptom confusion and attribution accounted for 56% of responses: women struggled to tell whether irregular sleep, mood changes, brain fog, or cycle shifts were perimenopause or something else entirely, including thyroid disease, premenstrual syndrome, or depression. Knowledge gaps and active information-seeking made up 28%, with many women holding age-based assumptions that perimenopause could not start before 45. Barriers to confirmation and care accounted for 16%, including dismissive clinical encounters and reluctance among some clinicians to consider perimenopause in women under 40.

What this means in Canada

Health Canada has not issued a standalone perimenopause diagnostic guideline, and there is no nationally approved biomarker test to confirm perimenopause stage. The SOGC (Society of Obstetricians and Gynaecologists of Canada) addressed menopause management in its clinical practice guidelines, most recently updated in 2021, but a dedicated perimenopause-specific position statement has not been published as of July 2026. The SOGC guidelines do affirm that hormone therapy, including estradiol (sold in Canada as Estrace in oral form and Estradot as a patch, among other formulations), is appropriate for managing perimenopausal symptoms in suitable candidates.

Provincial drug coverage for hormone therapy varies. In Ontario, OHIP does not cover the office visit cost of a menopause specialist beyond a general practitioner's fee, and most estradiol formulations require private insurance or out-of-pocket payment unless a patient qualifies under specific provincial drug benefit programs. In Quebec, RAMQ covers some hormone therapy formulations on its formulary for eligible patients. British Columbia's PharmaCare and Alberta's AHCIP each have their own formulary listings; patients should confirm coverage directly with their provincial plan. Canada's national pharmacare framework, still in development as of mid-2026, does not yet include a standardized menopause formulary.

For Canadians who cannot access a menopause-trained physician through their family doctor, several Canadian digital health platforms offer virtual consultations. Cleo (a Canadian women's health platform), Felix, Maple, and Science & Humans (scienceandhumans.com) all offer virtual care that can include hormone therapy prescribing, though the depth of menopause specialization varies by platform and by province. Telus Health also offers virtual primary care that may include menopause management. US-based platforms such as Midi Health and Hone Health do not serve Canadian patients.

Why this matters

The Menopause Society study is notable for its scale: most prior research on perimenopause uncertainty involved small samples or excluded women under 40. This study included women aged 35 and older, and found that younger women in the 35 to 39 age group were more likely to cite knowledge gaps as their primary source of confusion, partly because they assumed perimenopause was still years away. Women in the 40 to 44 group were most likely to report dismissive healthcare encounters.

The absence of a definitive diagnostic test is not a gap that will close soon. Follicle-stimulating hormone (FSH) levels are sometimes ordered by clinicians, but FSH fluctuates significantly during perimenopause and a single result cannot confirm or rule out the transition. The Menopause Society and the SOGC both caution against relying on FSH alone. Symptoms before menstrual irregularity begins, including sleep disruption, mood changes, and cognitive shifts, are recognized features of early perimenopause that clinicians may attribute to other causes.

Misinformation compounds the problem. Social media content about perimenopause has grown substantially since 2020, and while some of it reflects genuine patient experience, some promotes unproven diagnostics or supplements. The Menopause Society has noted a rise in misinformation about symptom management in recent years, and Health Canada has not endorsed any over-the-counter supplement as a perimenopause treatment.

What Canadian patients should know

If you are a woman over 35 experiencing symptoms such as irregular periods, sleep disruption, hot flashes, mood changes, or cognitive shifts, perimenopause is a reasonable possibility to raise with your doctor, even if your cycles are still relatively regular. The Menopause Society study found that many women experience significant symptoms before menstrual irregularity becomes obvious.

Bringing a written symptom log to your appointment, including timing, frequency, and severity, can help a clinician assess whether the pattern fits perimenopause or warrants investigation for other conditions such as thyroid dysfunction. A TSH (thyroid-stimulating hormone) test is often ordered alongside a clinical assessment to rule out thyroid disease, which shares several symptoms with perimenopause.

If your family physician is not familiar with perimenopause management, you can ask for a referral to a gynecologist or an internist with menopause training. The Menopause Society maintains a practitioner directory at menopause.org that includes some Canadian providers. The SOGC also provides patient-facing resources through its member clinicians.

Provincial differences matter for treatment access. If hormone therapy is appropriate for you, the specific formulation covered by your provincial drug plan may differ from what your clinician initially prescribes. A pharmacist can help identify covered alternatives within the same drug class.

Limitations and open questions

The Menopause Society study was conducted entirely in the United States, and its findings cannot be directly applied to Canadian populations without Canadian-specific data. Canada's demographic and healthcare-access profile differs from the US, particularly in rural and remote communities where access to any specialist, let alone a menopause-trained one, is limited.

The study relied on self-reported survey data, which introduces recall and response bias. It also did not capture women who had already received a perimenopause diagnosis, meaning the 34% uncertainty figure likely underestimates the proportion who were uncertain at some earlier point.

The SOGC has not yet issued a response to this study or updated its perimenopause-specific guidance in light of it. Health Canada has not issued guidance on perimenopause uncertainty as a public health concern. Whether Canadian research bodies such as CIHR (Canadian Institutes of Health Research) will fund a comparable Canadian-population study remains to be seen.

What the study does establish clearly is that uncertainty about perimenopause is common, that it peaks in the years when symptoms are often most disruptive, and that the healthcare system, in Canada as in the US, has not yet built the infrastructure to meet that need consistently.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.